Hamilton Thorne Ltd.

Hamilton Thorne Ltd.

Hamilton Thorne Ltd.

Overview
Date Founded

2009

Headquarters

100 Cummings Center,Suite 465E,Beverly, MA 01915-6143

Type of Company

Public

Employees (Worldwide)

11 - 50

Industries

Industrial Machinery & Manufacturing
Computer Software
Computer Hardware
Appliances & Electronics
Medical Support Services

Company Description

Hamilton Thorne Ltd. engages in the provision of laboratory instruments, consumables, software and services to the assisted reproductive technology (ART) and developmental biology research markets. Its brands include Hamilton Thorne, Embryotech, and Gynemed. The company was founded by Meg Spencer and Diarmaid H. Douglas-Hamilton on October 28, 2009 and is headquartered in Beverly, MA.

Executives & Employees

Director, President & Chief Executive Officer

Vice President, Finance & Chief Financial Officer

Secretary, Director & Chief Technology Officer

Senior Vice President & General Manager

Chief Strategic Advisor

Vice President, Engineering

Board of Directors

Director, President & Chief Executive Officer at Hamilton Thorne Ltd.

Secretary, Director & Chief Technology Officer at Hamilton Thorne Ltd.

Lecturer, Department of Biological Sciences at Columbia University

President at Technoventure, Inc.

President & Chief Executive Officer at Redan Capital, Inc.

Analyst at Cormark Securities, Inc.

Paths to Hamilton Thorne Ltd.
Potential Connections via
Relationship Science
You
Hamilton Thorne Ltd.
Owners & Shareholders
Details Hidden

AWM Investment uses a number of investment strategies and techniques involving equity or debt securities, including purchasing securities with borrowed money, selling securities short and purchasing and writing listed put and call options. Two of the funds they manages, SSFQP and the Cayman Fund, seek to maximize capital appreciation through general analysis of equity and equity-related securities, while the Tech Funds focus primarily on publicly traded companies that provide products and services in the communications, information and other technology-related fields. The Life Sciences Fund invests primarily in publicly traded equity of companies that provide products and services in health care, life sciences and related fields. The Private Equity Fund invests primarily in privately negotiated and privately placed equity and equity-related securities of publicly traded companies which possess a technological, market or product niche. The Innovation Fund invests in various seed, early and developmental stage private companies in the assisted reproductive technology sector.

Details Hidden

Norrep Capital Management has expertise in the energy sector and is widely known for their Flow-Through Limited Partnerships. The firm seeks to design products that can take advantage of market inefficiencies and that are difficult for investors to do on their own. Their investment solutions can be divided into a “wealth creation” arm and a “wealth preservation” arm. Norrep's suite of wealth creation products includes two Canadian small-cap funds, a micro-cap fund, Global, U.S. and Canadian all-cap funds, an energy fund, and a tactical balanced fund. Their wealth preservation side includes a global equity balanced fund, a Canadian equity balanced fund, a high yield fund and a short-term income fund. The firm also manages a market neutral income fund and a fund-of-funds. Norrep's investment process is based on a highly disciplined blend of fundamental and quantitative research. The firm focuses on optimizing such factors as return on equity, price to earnings, cash flow to debt, and yield that have historically led to outperformance over reasonable time periods. As value managers, Norrep seeks to limit downside when compared to their peers and benchmarks by avoiding speculative investments and remaining disciplined on how much they pay for a particular security.

Details Hidden

Norrep Capital Management has expertise in the energy sector and is widely known for their Flow-Through Limited Partnerships. The firm seeks to design products that can take advantage of market inefficiencies and that are difficult for investors to do on their own. Their investment solutions can be divided into a “wealth creation” arm and a “wealth preservation” arm. Norrep's suite of wealth creation products includes two Canadian small-cap funds, a micro-cap fund, Global, U.S. and Canadian all-cap funds, an energy fund, and a tactical balanced fund. Their wealth preservation side includes a global equity balanced fund, a Canadian equity balanced fund, a high yield fund and a short-term income fund. The firm also manages a market neutral income fund and a fund-of-funds. Norrep's investment process is based on a highly disciplined blend of fundamental and quantitative research. The firm focuses on optimizing such factors as return on equity, price to earnings, cash flow to debt, and yield that have historically led to outperformance over reasonable time periods. As value managers, Norrep seeks to limit downside when compared to their peers and benchmarks by avoiding speculative investments and remaining disciplined on how much they pay for a particular security.

Recent Transactions
Details Hidden

Hamilton Thorne Ltd. raised money in a private placement transaction

Details Hidden

Hamilton Thorne Ltd. purchases Gynemed GmbH & Co. KG

Details Hidden

Hamilton Thorne Ltd. raised money in a private placement transaction

Transaction Advisors
Investment Advisor

Advised onHamilton Thorne Ltd. purchases Embryotech Laboratories, Inc.

Legal Advisor

Advised onHamilton Thorne Ltd. purchases Gynemed GmbH & Co. KG

Legal Advisor

Advised onHamilton Thorne Ltd. purchases Gynemed GmbH & Co. KG

Legal Advisor

Advised onHamilton Thorne Ltd. purchases Gynemed GmbH & Co. KG

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

DuPont de Nemours, Inc. operates as a holding company, which engages in the development of specialty materials, chemicals, and agricultural products. It operates through the following segments: Electronics & Imaging; Nutrition & Biosciences; Transportation & Industrial; Safety & Construction, and Non-Core. The Electronics & Imaging segment provides permanent and process chemistries for the fabrication of printed circuit boards to include laminates and substrates, electroless and electrolytic metallization solutions, as well as patterning solutions and materials and innovative metallization processes for metal finishing, decorative, and industrial applications. The Nutrition & Biosciences segment provides solutions for the global food and beverage, dietary supplements, pharma, home and personal care, energy and animal nutrition markets. The Transportation & Industrial segment engineering resins, adhesives, silicones, lubricants and parts to engineers and designers in the transportation, electronics, healthcare, industrial and consumer end-markets to enable systems solutions for demanding applications and environments. The Safety & Construction segment provides engineering products and integrated systems for a number of industries including, worker safety, water purification and separation, aerospace, energy, medical packaging and building materials. The Non-Core segment supplier of key materials for the manufacturing of photovoltaic cells and panels, including SOLAMET metallization pastes, TEDLAR backsheet materials, and FORTASUN silicone encapsulants and adhesives. The company was founded in 1897 and is headquartered in Wilmington, DE.

Key Stats and Financials As of 2019
Market Capitalization
$150M
Total Enterprise Value
$99.8M
Earnings Per Share
$0.01
EBITDAMargin
17.46%
Enterprise Value / Sales
2.91x
Enterprise Value EBITDAOperating
16.64x
TEVNet Income
129.54x
Debt TEV
0.11x
Three Year Compounded Annual Growth Rate Of Revenue
49.89%
Five Year Compounded Annual Growth Rate Of Revenue
37.53%
Revenue
$34.4M
Net Profit
$769K
EBITDA
$6M
Total Debt
$11.2M
Total Equity
$36.8M
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Hamilton Thorne Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Hamilton Thorne Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Hamilton Thorne Ltd..